Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:mixed diacylamine
go back to main search page
Accession:CHEBI:37716 term browser browse the term
Definition:Any imide in which the acyl substituents are any two from carboacyl, sulfonyl and phosphoryl
Synonyms:related_synonym: mixed diacylamines



show annotations for term's descendants           Sort by:
 
ABT-737 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]] CTD PMID:32802178 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Bag3 BAG cochaperone 3 decreases response to substance
multiple interactions
ISO BAG3 protein results in decreased susceptibility to ABT-737
[BAG3 protein results in increased stability of MCL1 protein] which results in decreased susceptibility to ABT-737; BAG3 mutant form inhibits the reaction [MCL1 protein results in decreased susceptibility to ABT-737]
CTD PMID:23341456 NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
JBrowse link
G Bax BCL2 associated X, apoptosis regulator affects folding
multiple interactions
ISO ABT-737 affects the folding of BAX protein
[ABT-737 co-treated with Etoposide] affects the folding of and results in increased activity of BAX protein; [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; ABT-737 inhibits the reaction [BAX protein binds to BCL2 protein]
CTD PMID:17097560 PMID:17200714 PMID:21880625 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases response to substance
ISO ABT-737 inhibits the reaction [BCL2 protein results in decreased susceptibility to Valproic Acid]; ABT-737 inhibits the reaction [BCL2 protein results in decreased susceptibility to Vorinostat]
[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased phosphorylation of BCL2 protein] which results in increased susceptibility to ABT-737; [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; [ABT-737 results in decreased activity of BCL2 protein] which results in increased susceptibility to fosbretabulin; [BCL2L11 protein binds to BCL2 protein] which affects the susceptibility to ABT-737; ABT-737 inhibits the reaction [BAX protein binds to BCL2 protein]; ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]; ABT-737 inhibits the reaction [Silicon Dioxide promotes the reaction [BCL2 protein binds to BECN1 protein]]; BCL2 protein inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]
BCL2 protein modified form results in decreased susceptibility to ABT-737
CTD PMID:17097560 PMID:17200714 PMID:19060243 PMID:20104024 PMID:24321340 More... NCBI chr13:22,689,783...22,853,920 JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
increases expression
ISO ABT-737 inhibits the reaction [BCL2L1 protein results in decreased susceptibility to Valproic Acid]; ABT-737 inhibits the reaction [BCL2L1 protein results in decreased susceptibility to Vorinostat]
ABT-737 inhibits the reaction [Cholecalciferol promotes the reaction [BECN1 protein binds to BCL2L1 protein]]
ABT-737 results in increased expression of BCL2L1 protein alternative form
CTD PMID:18628207 PMID:19060243 PMID:21256112 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases response to substance
ISO [ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]] promotes the reaction [BCL2L11 protein results in increased activity of BAX protein]; [BCL2L11 protein binds to BCL2 protein] which affects the susceptibility to ABT-737; [MCL1 protein results in decreased activity of BCL2L11 protein] which results in decreased susceptibility to ABT-737; ABT-737 inhibits the reaction [BCL2L11 protein binds to BCL2 protein]
BCL2L11 protein results in increased susceptibility to ABT-737
CTD PMID:17097560 PMID:17200714 PMID:20038611 PMID:23341456 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
JBrowse link
G Becn1 beclin 1 multiple interactions ISO ABT-737 inhibits the reaction [Cholecalciferol promotes the reaction [BECN1 protein binds to BCL2L1 protein]]; ABT-737 inhibits the reaction [Silicon Dioxide promotes the reaction [BCL2 protein binds to BECN1 protein]] CTD PMID:18628207 PMID:32061152 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [ABT-737 co-treated with Celecoxib] results in increased cleavage of BID protein CTD PMID:20104024 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase multiple interactions ISO ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]] CTD PMID:27689874 NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
increases activity
ISO ABT-737 results in increased cleavage of CASP3 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; [[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP3 protein; [Quercetin results in increased susceptibility to ABT-737] which results in increased activity of CASP3 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]
ABT-737 results in increased activity of CASP3 protein
CTD PMID:19010845 PMID:19773376 PMID:20038611 PMID:20104024 PMID:23353698 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp7 caspase 7 increases activity ISO ABT-737 results in increased activity of CASP7 protein CTD PMID:20038611 NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
JBrowse link
G Casp8 caspase 8 increases cleavage
multiple interactions
ISO ABT-737 results in increased cleavage of CASP8 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP8 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]
CTD PMID:20104024 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Casp9 caspase 9 increases activity
increases cleavage
multiple interactions
ISO ABT-737 results in increased activity of CASP9 protein
ABT-737 results in increased cleavage of CASP9 protein
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]; [ABT-737 co-treated with Celecoxib] results in increased activity of CASP9 protein; [Quercetin results in increased susceptibility to ABT-737] which results in increased activity of CASP9 protein; ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]; ABT-737 promotes the reaction [Wortmannin promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]; Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein]
CTD PMID:20104024 PMID:23353698 PMID:30461186 PMID:33662508 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]] CTD PMID:27689874 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
JBrowse link
G Krt18 keratin 18 increases cleavage ISO ABT-737 results in increased cleavage of KRT18 protein CTD PMID:19010845 NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; MAP1LC3B mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein] CTD PMID:20104024 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member decreases response to substance
multiple interactions
ISO MCL1 protein results in decreased susceptibility to ABT-737
[BAG3 protein results in increased stability of MCL1 protein] which results in decreased susceptibility to ABT-737; [Cycloheximide co-treated with MCL1] results in increased susceptibility to ABT-737; [MCL1 protein results in decreased activity of BCL2L11 protein] which results in decreased susceptibility to ABT-737; BAG3 mutant form inhibits the reaction [MCL1 protein results in decreased susceptibility to ABT-737]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]
CTD PMID:17097560 PMID:17688235 PMID:21880625 PMID:23341456 PMID:32802178 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]] CTD PMID:27689874 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions
decreases expression
ISO [ABT-737 co-treated with Sirolimus] results in decreased expression of MKI67 protein
ABT-737 results in decreased expression of MKI67 protein
CTD PMID:19773376 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
JBrowse link
G Nanog Nanog homeobox decreases expression ISO ABT-737 results in decreased expression of NANOG protein CTD PMID:23918355 NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein; AKT1 protein modified form inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein inhibits the reaction [Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; MCL1 protein promotes the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; Wortmannin inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein] CTD PMID:32802178 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pik3c3 phosphatidylinositol 3-kinase, catalytic subunit type 3 multiple interactions ISO PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP8 protein]; PIK3C3 mutant form promotes the reaction [[Celecoxib co-treated with ABT-737] results in increased cleavage of CASP9 protein] CTD PMID:20104024 NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048
JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 increases response to substance ISO PMAIP1 protein results in increased susceptibility to ABT-737 CTD PMID:17688235 NCBI chr18:59,986,187...59,990,174
Ensembl chr18:59,986,017...59,992,429
JBrowse link
G Rassf1 Ras association domain family member 1 multiple interactions ISO ABT-737 promotes the reaction [RASSF1 results in increased susceptibility to Cisplatin]; ABT-737 promotes the reaction [RASSF1 results in increased susceptibility to Etoposide] CTD PMID:21880625 NCBI chr 8:108,225,023...108,236,164
Ensembl chr 8:108,225,023...108,236,164
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO [Celecoxib co-treated with ABT-737] results in decreased expression of SQSTM1 protein; ABT-737 promotes the reaction [Silicon Dioxide results in decreased expression of SQSTM1 protein] CTD PMID:20104024 PMID:32061152 NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
JBrowse link
G Usp7 ubiquitin specific peptidase 7 multiple interactions ISO USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; USP7 protein affects the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein] CTD PMID:32802178 NCBI chr10:6,880,684...6,925,033
Ensembl chr10:6,828,795...6,925,355
JBrowse link
acephate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ache acetylcholinesterase multiple interactions
decreases activity
ISO
EXP
methamidophos inhibits the reaction [acephate results in decreased activity of ACHE protein] CTD PMID:9074804 PMID:11048668 PMID:12039681 PMID:22778074 PMID:23000449 NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
JBrowse link
G Alad aminolevulinate dehydratase decreases activity ISO acephate results in decreased activity of ALAD protein CTD PMID:8687997 NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474
JBrowse link
G Alpl alkaline phosphatase, biomineralization associated multiple interactions ISO acephate inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA] CTD PMID:29149346 NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
JBrowse link
G Bche butyrylcholinesterase decreases expression EXP acephate results in decreased expression of BCHE protein CTD PMID:31326399 NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
JBrowse link
G Cat catalase multiple interactions
decreases activity
EXP [acephate co-treated with methamidophos co-treated with Nicotine] results in increased activity of CAT protein; [Phorate co-treated with acephate co-treated with Dichlorvos co-treated with Dimethoate] results in decreased activity of CAT protein
acephate results in decreased activity of CAT protein
CTD PMID:10874619 PMID:22034174 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Crh corticotropin releasing hormone increases expression
multiple interactions
increases secretion
EXP acephate results in increased expression of CRH mRNA
acephate promotes the reaction [FOS protein binds to CRH promoter]; Atropine inhibits the reaction [acephate results in increased expression of CRH mRNA]; Atropine inhibits the reaction [acephate results in increased secretion of CRH protein]; gamma-Aminobutyric Acid inhibits the reaction [acephate results in increased expression of CRH mRNA]; gamma-Aminobutyric Acid inhibits the reaction [acephate results in increased secretion of CRH protein]; Propranolol inhibits the reaction [acephate results in increased expression of CRH mRNA]; Propranolol inhibits the reaction [acephate results in increased secretion of CRH protein]
CTD PMID:12039681 NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO [acephate co-treated with vinclozolin] affects the expression of CYP1A1 protein; [fenarimol co-treated with acephate] affects the expression of CYP1A1 protein; [fenarimol co-treated with vinclozolin co-treated with acephate] affects the expression of CYP1A1 protein CTD PMID:17686559 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO [fenarimol co-treated with acephate] affects the expression of CYP1A2 protein; [fenarimol co-treated with vinclozolin co-treated with acephate] affects the expression of CYP1A2 protein CTD PMID:17686559 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 multiple interactions ISO [acephate co-treated with vinclozolin] affects the expression of CYP2B1 protein; [fenarimol co-treated with acephate] affects the expression of CYP2B1 protein; [fenarimol co-treated with vinclozolin co-treated with acephate] affects the expression of CYP2B1 protein CTD PMID:17686559 NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
JBrowse link
G Cyp2b2 cytochrome P450, family 2, subfamily b, polypeptide 2 multiple interactions ISO [acephate co-treated with vinclozolin] affects the expression of CYP2B2 protein; [fenarimol co-treated with acephate] affects the expression of CYP2B2 protein; [fenarimol co-treated with vinclozolin co-treated with acephate] affects the expression of CYP2B2 protein CTD PMID:17686559 NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO [acephate co-treated with vinclozolin] affects the expression of CYP2E1 protein; [fenarimol co-treated with acephate] affects the expression of CYP2E1 protein; [fenarimol co-treated with vinclozolin co-treated with acephate] affects the expression of CYP2E1 protein CTD PMID:17686559 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP acephate promotes the reaction [FOS protein binds to CRH promoter] CTD PMID:12039681 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 multiple interactions
increases activity
EXP diphenyldiselenide inhibits the reaction [acephate results in increased activity of G6PC1 protein] CTD PMID:22778074 NCBI chr10:86,307,400...86,318,766 JBrowse link
G Gpt glutamic--pyruvic transaminase decreases expression EXP acephate results in decreased expression of GPT protein CTD PMID:33217513 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Nr3c2 nuclear receptor subfamily 3, group C, member 2 multiple interactions ISO acephate inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; acephate inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein] CTD PMID:29149346 NCBI chr19:30,715,648...31,059,885
Ensembl chr19:30,715,648...31,059,885
JBrowse link
G Tat tyrosine aminotransferase multiple interactions
increases activity
EXP diphenyldiselenide inhibits the reaction [acephate results in increased activity of TAT protein] CTD PMID:19118596 PMID:22778074 NCBI chr19:37,947,153...37,957,717
Ensembl chr19:37,947,112...37,958,031
JBrowse link
fomesafen term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcd3 ATP binding cassette subfamily D member 3 increases expression ISO fomesafen results in increased expression of ABCD3 mRNA CTD PMID:22539621 NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020
JBrowse link
G Acot1 acyl-CoA thioesterase 1 increases expression ISO fomesafen results in increased expression of ACOT1 mRNA CTD PMID:22539621 NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
JBrowse link
G Acox1 acyl-CoA oxidase 1 increases expression ISO fomesafen results in increased expression of ACOX1 mRNA CTD PMID:22539621 NCBI chr10:101,406,197...101,431,242
Ensembl chr10:101,406,197...101,431,232
JBrowse link
G Alas1 5'-aminolevulinate synthase 1 increases expression ISO fomesafen results in increased expression of ALAS1 mRNA CTD PMID:12758057 NCBI chr 8:106,876,514...106,889,852
Ensembl chr 8:106,876,514...106,889,917
JBrowse link
G Urod uroporphyrinogen decarboxylase decreases activity ISO fomesafen results in decreased activity of UROD protein CTD PMID:12758057 NCBI chr 5:130,464,695...130,468,783
Ensembl chr 5:130,455,217...130,468,808
JBrowse link
navitoclax term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bak1 BCL2-antagonist/killer 1 multiple interactions ISO [navitoclax co-treated with Vorinostat] affects the activity of BAK1 protein CTD PMID:21652541 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [navitoclax co-treated with Vorinostat] affects the activity of BAX protein CTD PMID:21652541 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression
multiple interactions
ISO navitoclax results in decreased expression of BIRC5 protein
[MTOR protein affects the susceptibility to navitoclax] which affects the expression of BIRC5 protein; navitoclax promotes the reaction [Everolimus results in decreased expression of BIRC5 protein]
CTD PMID:28947240 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
ISO navitoclax results in increased cleavage of CASP3 protein
[navitoclax co-treated with Vorinostat] results in increased activity of CASP3 protein
CTD PMID:21562047 PMID:21652541 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 increases cleavage ISO navitoclax results in increased cleavage of CASP9 protein CTD PMID:21562047 PMID:28947240 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Gsn gelsolin increases cleavage ISO navitoclax results in increased cleavage of GSN protein CTD PMID:21562047 NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402
JBrowse link
G Mtor mechanistic target of rapamycin kinase affects response to substance
multiple interactions
ISO MTOR protein affects the susceptibility to navitoclax
[MTOR protein affects the susceptibility to navitoclax] which affects the cleavage of PARP1 protein; [MTOR protein affects the susceptibility to navitoclax] which affects the expression of BIRC5 protein
CTD PMID:28947240 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
ISO [MTOR protein affects the susceptibility to navitoclax] which affects the cleavage of PARP1 protein; [navitoclax co-treated with Everolimus] results in increased cleavage of PARP1 protein
navitoclax results in increased cleavage of PARP1 protein
CTD PMID:28947240 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
parecoxib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cnr1 cannabinoid receptor 1 increases response to substance ISO CNR1 protein results in increased susceptibility to parecoxib CTD PMID:23371449 NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
JBrowse link
saccharin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Afp alpha-fetoprotein increases expression ISO Saccharin results in increased expression of AFP mRNA CTD PMID:26272751 NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
JBrowse link
G Ca13 carbonic anhydrase 13 increases expression ISO Saccharin results in increased expression of CAR13 mRNA CTD PMID:19000923 NCBI chr 2:86,928,401...86,959,525
Ensembl chr 2:86,928,383...86,959,525
JBrowse link
G Ca3 carbonic anhydrase 3 multiple interactions ISO Saccharin binds to and results in decreased activity of CA3 protein CTD PMID:17826101 NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
JBrowse link
G Cdk1 cyclin-dependent kinase 1 increases expression ISO Saccharin results in increased expression of CDK1 mRNA CTD PMID:26272751 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
JBrowse link
G Cer1 cerberus 1, DAN family BMP antagonist increases expression ISO Saccharin results in increased expression of CER1 mRNA CTD PMID:26272751 NCBI chr 5:97,306,427...97,309,783
Ensembl chr 5:97,306,431...97,309,783
JBrowse link
G Chek1 checkpoint kinase 1 increases expression ISO Saccharin results in increased expression of CHEK1 mRNA CTD PMID:19000923 NCBI chr 8:36,420,565...36,443,477 JBrowse link
G Fosl1 FOS like 1, AP-1 transcription factor subunit increases expression ISO Saccharin results in increased expression of FOSL1 mRNA CTD PMID:19000923 NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
JBrowse link
G Gnat3 G protein subunit alpha transducin 3 affects response to substance ISO GNAT3 protein affects the susceptibility to Saccharin CTD PMID:16740645 NCBI chr 4:17,162,500...17,212,283
Ensembl chr 4:17,162,490...17,212,283
JBrowse link
G Hdac7 histone deacetylase 7 decreases expression ISO Saccharin results in decreased expression of HDAC7 mRNA CTD PMID:26272751 NCBI chr 7:128,923,918...128,962,025
Ensembl chr 7:128,923,920...128,962,072
JBrowse link
G Hells helicase, lymphoid specific increases expression ISO Saccharin results in increased expression of HELLS mRNA CTD PMID:19000923 NCBI chr 1:236,701,704...236,748,239
Ensembl chr 1:236,701,758...236,746,844
JBrowse link
G Il1rl1 interleukin 1 receptor-like 1 increases expression ISO Saccharin results in increased expression of IL1RL1 mRNA CTD PMID:19000923 NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression ISO Saccharin results in increased expression of JUN mRNA CTD PMID:19000923 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit increases expression ISO Saccharin results in increased expression of JUNB mRNA CTD PMID:19000923 NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
JBrowse link
G Kdr kinase insert domain receptor increases expression ISO Saccharin results in increased expression of KDR mRNA CTD PMID:26272751 NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
JBrowse link
G Mcm3 minichromosome maintenance complex component 3 increases expression ISO Saccharin results in increased expression of MCM3 mRNA CTD PMID:19000923 NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314
JBrowse link
G Mesp1 mesoderm posterior bHLH transcription factor 1 decreases expression ISO Saccharin results in decreased expression of MESP1 mRNA CTD PMID:26272751 NCBI chr 1:133,738,357...133,739,875
Ensembl chr 1:133,738,357...133,739,875
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases expression ISO Saccharin results in increased expression of MYC mRNA CTD PMID:26272751 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Myo1e myosin IE increases expression ISO Saccharin results in increased expression of MYO1E mRNA CTD PMID:26272751 NCBI chr 8:70,887,934...71,080,180
Ensembl chr 8:70,887,870...71,080,169
JBrowse link
G Nes nestin increases expression ISO Saccharin results in increased expression of NES mRNA CTD PMID:26272751 NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777
JBrowse link
G Nos2 nitric oxide synthase 2 increases expression ISO Saccharin results in increased expression of NOS2 mRNA CTD PMID:28472674 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nup54 nucleoporin 54 increases expression ISO Saccharin results in increased expression of NUP54 mRNA CTD PMID:19000923 NCBI chr14:15,617,630...15,636,029
Ensembl chr14:15,617,679...15,636,028
JBrowse link
G Orm1 orosomucoid 1 increases expression ISO Saccharin results in increased expression of ORM1 mRNA CTD PMID:19000923 NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
JBrowse link
G Phex phosphate regulating endopeptidase homolog, X-linked increases expression ISO Saccharin results in increased expression of PHEX mRNA CTD PMID:19000923 NCBI chr  X:37,607,553...37,856,183
Ensembl chr  X:37,610,760...37,854,469
JBrowse link
G Pik3r5 phosphoinositide-3-kinase, regulatory subunit 5 increases expression ISO Saccharin results in increased expression of PIK3R5 mRNA CTD PMID:19000923 NCBI chr10:53,132,585...53,200,663
Ensembl chr10:53,132,603...53,199,374
JBrowse link
G Pnpla6 patatin-like phospholipase domain containing 6 decreases expression ISO Saccharin results in decreased expression of PNPLA6 mRNA CTD PMID:26272751 NCBI chr12:1,574,387...1,603,735
Ensembl chr12:1,560,363...1,603,734
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO [Saccharin co-treated with Glucose] binds to PPARA protein; Saccharin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] CTD PMID:18812576 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
JBrowse link
G Rad21 RAD21 cohesin complex component increases expression ISO Saccharin results in increased expression of RAD21 mRNA CTD PMID:19000923 NCBI chr 7:83,287,867...83,314,810
Ensembl chr 7:83,287,870...83,314,817
JBrowse link
G Rif1 replication timing regulatory factor 1 increases expression ISO Saccharin results in increased expression of RIF1 mRNA CTD PMID:19000923 NCBI chr 3:36,554,689...36,607,961
Ensembl chr 3:36,554,697...36,603,617
JBrowse link
G Scarb1 scavenger receptor class B, member 1 increases expression ISO Saccharin results in increased expression of SCARB1 mRNA CTD PMID:19000923 NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
JBrowse link
G Shh sonic hedgehog signaling molecule decreases expression ISO Saccharin results in decreased expression of SHH mRNA CTD PMID:26272751 NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
JBrowse link
G Slc2a1 solute carrier family 2 member 1 increases expression ISO Saccharin results in increased expression of SLC2A1 mRNA CTD PMID:19000923 NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
JBrowse link
G Stmn1 stathmin 1 increases expression ISO Saccharin results in increased expression of STMN1 mRNA CTD PMID:19000923 NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154
JBrowse link
G Tas1r3 taste 1 receptor member 3 affects response to substance
multiple interactions
ISO TAS1R3 protein affects the susceptibility to Saccharin
TRPV1 protein affects the reaction [TAS1R3 protein affects the susceptibility to Saccharin]
CTD PMID:18804451 NCBI chr 5:166,469,589...166,472,742
Ensembl chr 5:166,469,589...166,472,742
JBrowse link
G Tas2r136 taste receptor, type 2, member 136 increases activity ISO Saccharin results in increased activity of TAS2R31 protein CTD PMID:21629661 NCBI chr 4:166,098,848...166,099,840
Ensembl chr 4:166,098,848...166,099,840
JBrowse link
G Tfrc transferrin receptor increases expression ISO Saccharin results in increased expression of TFRC mRNA CTD PMID:19000923 NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
JBrowse link
G Tnf tumor necrosis factor increases expression ISO Saccharin results in increased expression of TNF mRNA CTD PMID:28472674 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 multiple interactions
increases activity
ISO TRPV1 protein affects the reaction [TAS1R3 protein affects the susceptibility to Saccharin]
Saccharin results in increased activity of TRPV1 protein
CTD PMID:17567713 PMID:18804451 NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO Saccharin results in increased expression of VEGFA mRNA CTD PMID:19000923 PMID:26272751 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
G Wnt3 Wnt family member 3 increases expression ISO Saccharin results in increased expression of WNT3 mRNA CTD PMID:26272751 NCBI chr10:88,680,248...88,724,170
Ensembl chr10:88,680,248...88,724,099
JBrowse link
sulfacetamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hmbs hydroxymethylbilane synthase decreases activity EXP Sulfacetamide decreases activity of purified Hmbs protein RGD PMID:6893114 RGD:26923963 NCBI chr 8:44,673,554...44,680,950
Ensembl chr 8:44,673,554...44,680,957
JBrowse link
venetoclax term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcg2 ATP binding cassette subfamily G member 2 affects binding ISO venetoclax binds to ABCG2 protein CTD PMID:33954893 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases activity ISO venetoclax results in decreased activity of BCL2 protein CTD PMID:26214592 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [YM 155 co-treated with venetoclax] results in decreased expression of BIRC5 protein CTD PMID:31837377 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [venetoclax co-treated with YM 155] results in increased cleavage of CASP3 protein CTD PMID:31837377 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [venetoclax co-treated with YM 155] results in increased cleavage of CASP9 protein CTD PMID:31837377 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member increases expression
multiple interactions
ISO venetoclax results in increased expression of MCL1 protein
[YM 155 co-treated with venetoclax] results in decreased expression of MCL1 protein
CTD PMID:31837377 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [venetoclax co-treated with YM 155] results in increased cleavage of PARP1 protein CTD PMID:31837377 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
zafirlukast term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO zafirlukast results in decreased activity of ABCB11 protein CTD PMID:23956101 PMID:28437613 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 decreases activity ISO zafirlukast results in decreased activity of ABCB4 protein CTD PMID:28437613 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions ISO zafirlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine] CTD PMID:15180633 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
JBrowse link
G Bmp6 bone morphogenetic protein 6 increases expression ISO zafirlukast results in increased expression of BMP6 mRNA CTD PMID:32816093 NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
JBrowse link
G Cat catalase increases expression EXP zafirlukast results in increased expression of CAT protein CTD PMID:12962976 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO zafirlukast inhibits the reaction [CYP1A2 protein results in increased metabolism of Theophylline] CTD PMID:9701106 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
G Cyp2c6v1 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 multiple interactions
decreases activity
ISO zafirlukast inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]
zafirlukast results in decreased activity of CYP2C19 protein
CTD PMID:15370959 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 decreases activity ISO zafirlukast results in decreased activity of CYP2C8 protein CTD PMID:15601807
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 decreases activity
multiple interactions
increases metabolic processing
ISO zafirlukast metabolite results in decreased activity of CYP3A4 protein; zafirlukast results in decreased activity of CYP3A4 protein
zafirlukast inhibits the reaction [CYP3A4 protein results in increased metabolism of Midazolam]
CYP3A4 protein results in increased metabolism of zafirlukast
CTD PMID:15370959 PMID:16167835 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Cysltr1 cysteinyl leukotriene receptor 1 multiple interactions
affects binding
ISO [zafirlukast binds to and results in decreased activity of CYSLTR1 protein] which affects the abundance of Calcium; alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol inhibits the reaction [zafirlukast binds to and results in decreased activity of CYSLTR1 protein]; zafirlukast binds to and results in decreased activity of CYSLTR1 protein; zafirlukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein]; zafirlukast inhibits the reaction [[Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; zafirlukast inhibits the reaction [[Uridine Diphosphate metabolite results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein]; zafirlukast inhibits the reaction [CYSLTR1 protein promotes the reaction [Leukotriene D4 results in increased abundance of Calcium]]; zafirlukast inhibits the reaction [CYSLTR1 protein results in increased susceptibility to Leukotriene D4]; zafirlukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; zafirlukast inhibits the reaction [Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein]
zafirlukast binds to and results in decreased activity of CYSLTR1 protein; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]
zafirlukast binds to CYSLTR1 protein
CTD PMID:1554195 PMID:8014876 PMID:8384568 PMID:8389103 PMID:8389105 More... NCBI chr  X:71,661,415...71,690,158
Ensembl chr  X:71,663,821...71,690,121
JBrowse link
G Cysltr2 cysteinyl leukotriene receptor 2 multiple interactions ISO zafirlukast binds to and results in decreased activity of CYSLTR2 protein; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR2 protein] CTD PMID:10851239 NCBI chr15:48,190,251...48,229,906
Ensembl chr15:48,189,073...48,304,136
JBrowse link
G Edn1 endothelin 1 multiple interactions
decreases expression
ISO zafirlukast inhibits the reaction [Leukotriene C4 results in increased expression of EDN1 mRNA]; zafirlukast inhibits the reaction [Leukotriene C4 results in increased expression of EDN1 protein]
zafirlukast results in decreased expression of EDN1 protein
CTD PMID:11372388 PMID:12781059 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
JBrowse link
G Ereg epiregulin increases expression ISO zafirlukast results in increased expression of EREG mRNA CTD PMID:32816093 NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
JBrowse link
G Ifng interferon gamma multiple interactions ISO [zafirlukast co-treated with Prednisone co-treated with Budesonide] inhibits the reaction [Antigens results in increased secretion of IFNG protein] CTD PMID:16160912 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Il1b interleukin 1 beta decreases expression ISO zafirlukast results in decreased expression of IL1B mRNA CTD PMID:32816093 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il24 interleukin 24 increases expression ISO zafirlukast results in increased expression of IL24 mRNA CTD PMID:32816093 NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
JBrowse link
G Il6 interleukin 6 multiple interactions ISO zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein] CTD PMID:18704935 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase increases expression ISO zafirlukast results in increased expression of MET mRNA CTD PMID:32816093 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP2 mRNA]; zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP2 protein] CTD PMID:31816286 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP9 mRNA]; zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP9 protein] CTD PMID:31816286 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
JBrowse link
G Mpo myeloperoxidase decreases activity
decreases expression
EXP zafirlukast results in decreased activity of MPO protein
zafirlukast results in decreased expression of MPO protein
CTD PMID:11438310 PMID:12962976 NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
JBrowse link
G Ocln occludin multiple interactions ISO zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of OCLN mRNA]; zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of OCLN protein] CTD PMID:31816286 NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
JBrowse link
G Pid1 phosphotyrosine interaction domain containing 1 increases expression ISO zafirlukast results in increased expression of PID1 mRNA CTD PMID:32816093 NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression ISO zafirlukast results in increased expression of PTGS2 mRNA CTD PMID:32816093 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Rnase3 ribonuclease A family member 3 decreases expression ISO zafirlukast results in decreased expression of RNASE3 protein CTD PMID:15612964 NCBI chr15:24,511,894...24,512,764
Ensembl chr15:24,511,891...24,512,790
JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO zafirlukast inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
JBrowse link
G Slc47a1 solute carrier family 47 member 1 multiple interactions ISO zafirlukast inhibits the reaction [SLC47A1 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
JBrowse link
G Slc47a2 solute carrier family 47 member 2 multiple interactions ISO zafirlukast inhibits the reaction [SLC47A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904
JBrowse link
G Slc7a11 solute carrier family 7 member 11 decreases expression ISO zafirlukast results in decreased expression of SLC7A11 mRNA CTD PMID:32816093 NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
JBrowse link
G Slpi secretory leukocyte peptidase inhibitor increases expression ISO zafirlukast results in increased expression of SLPI mRNA CTD PMID:32816093 NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
JBrowse link
G Tjp1 tight junction protein 1 multiple interactions ISO zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of TJP1 mRNA]; zafirlukast inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of TJP1 protein] CTD PMID:31816286 NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein] CTD PMID:18704935 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfaip6 TNF alpha induced protein 6 decreases expression ISO zafirlukast results in decreased expression of TNFAIP6 mRNA CTD PMID:32816093 NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19810
    chemical entity 19810
      atom 19809
        nonmetal atom 19696
          nitrogen atom 18759
            nitrogen molecular entity 18759
              amide 17554
                secondary amide 6094
                  imide 6093
                    mixed diacylamine 122
                      N-sulfonylcarboxamide + 108
                      acephate 16
Path 2
Term Annotations click to browse term
  CHEBI ontology 19810
    subatomic particle 19809
      composite particle 19809
        hadron 19809
          baryon 19809
            nucleon 19809
              atomic nucleus 19809
                atom 19809
                  main group element atom 19706
                    p-block element atom 19706
                      pnictogen 18839
                        nitrogen atom 18759
                          nitrogen molecular entity 18759
                            amide 17554
                              secondary amide 6094
                                imide 6093
                                  mixed diacylamine 122
                                    N-sulfonylcarboxamide + 108
                                    acephate 16
paths to the root